Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Seeking Alpha
Intellia Therapeutics, Inc. (NASDAQ: NTLA Company Participants Lina Li - Associate Director, IR John Leonard - President, CEO & Director Laura Sepp-Lorenzino - EVP & Chief Scientific Officer Glenn Goddard - EVP & CFO Conference Call Participants Maurice Raycroft - Jefferies David Allen - Barclays Mani Foroohar - SVB Leerink Madhu Kumar - Robert W. Baird & Co. Steven Seedhouse - Raymond James & Associates Max Smock - BTIG Silvan Tuerkcan - Oppenheimer Operator Good morning. My name is Andrew, and I will be your conference operator today, and welcome to the Intellia Therapeutics Fourth Quarter and Full Year 2019 Financial Results Conference Call. [Operator Instructions]. At this time, I would like to turn it over to Lina Li, Associate Director of Investor Relations at Intellia. Please proceed. Thank you, Operator. Good morning, and thank you all for joining us today to discuss Intellia's fourth quarter and full year 2019 operational highlights and financial results. Earlier this morning
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Rob Lauzon's Top Picks: March 25, 2024 [BNN Bloomberg (Canada)]BNN Bloomberg
- Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyGlobeNewswire
- Is Intellia Therapeutics Stock a Buy Now? [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 2/22/24 - Beat
NTLA
Sec Filings
- 3/22/24 - Form 8-K
- 3/5/24 - Form 4
- 3/5/24 - Form 4
- NTLA's page on the SEC website